title: Recent advances in oral vaccine development: yeast-derived β-glucan particles.
abstract: Oral vaccination is the most challenging vaccination method due to the administration route. However, oral vaccination has socio-economic benefits and provides the possibility of stimulating both humoral and cellular immune responses at systemic and mucosal sites. Despite the advantages of oral vaccination, only a limited number of oral vaccines are currently approved for human use. During the last decade, extensive research regarding antigen-based oral vaccination methods have improved immunogenicity and induced desired immunological outcomes. Nevertheless, several factors such as the harsh gastro-intestinal environment and oral tolerance impede the clinical application of oral delivery systems. To date, human clinical trials investigating the efficacy of these systems are still lacking. This review addresses the rationale and key biological and physicochemical aspects of oral vaccine design and highlights the use of yeast-derived β-glucan microparticles as an oral vaccine delivery platform.
authors.affiliation: Department of Pathology; Ghent University; Ghent, Belgium.
authors.forename: Rebecca
authors.initials: R
authors.lastname: De Smet
authors.affiliation: Department of Pathology; Ghent University; Ghent, Belgium.
authors.forename: Liesbeth
authors.initials: L
authors.lastname: Allais
authors.affiliation: Department of Pathology; Ghent University; Ghent, Belgium.
authors.forename: Claude A
authors.initials: CA
authors.lastname: Cuvelier
mesh_terms: D000284:Administration, Oral; D000818:Animals; D016503:Drug Delivery Systems / Q000639:trends; D055808:Drug Discovery / Q000639:trends*; D006801:Humans; D008863:Microspheres; D012441:Saccharomyces cerevisiae / Q000276:immunology*; D014612:Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D015003:Yeasts / Q000276:immunology; D047071:beta-Glucans / Q000008:administration & dosage* / Q000276:immunology*
chemical_list: D014612:Vaccines; D047071:beta-Glucans
keywords: GALT; Peyer’s patches; antigen delivery vehicles; microparticles; oral; vaccination; yeast-derived beta-glucan